Testing mirdametinib, alone or with radiation, for NF1-related high-grade glioma
Original title: Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called mirdametinib in people with high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary tied to NF1 gene changes.
Who this trial is for. This trial is for people with high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary that has NF1 gene changes. It tests the drug mirdametinib, either with radiation or on its own.
Where it stands. This trial has not reported results. It is measuring how well mirdametinib works in these groups. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Someone whose tumor has NF1 gene changes may want to ask their care team about this trial. The care team can say if it fits their case.
What it doesn't mean: This does not mean mirdametinib is a proven treatment. A trial is a test, not care your own doctor can give you. Being in a trial is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.